Head-to-head dispatch
Eden vs Oak
Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.
Desk Score
High-disclosure compounded program — the clearest verification signals in the ranking, at a premium price.
Marked down on: Premium pricing relative to peers
FDAWarning letter issued to Eden Health International Inc. dba Eden in June 2026. See the FDA warning-letter database.
Desk Score
Nationwide, package-based and quick to approve, at $200/mo for compounded semaglutide and $250 for tirzepatide — one flat rate at every dose. The catch is not secrecy but inconsistency: its advertising carries nine different "starting" prices and none of them is what it charges.
Marked down on: Oak's MARKETING layer publishes nine different "starting" figures — $119, $133, $160, $167, $180, $185, $190, $199 and $250 — and attaches a term or billing cadence to none of them. None of the nine is what it charges: its own funnel quotes $200/mo semaglutide and $250/mo tirzepatide, one flat rate at every dose
Eden takes this head-to-head with the higher Desk Score, 85/100 (B) against 71/100 (C) for Oak. Oak still holds its ground where its strengths line up with yours.
Desk Score, dimension by dimension
Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.
Eden
85/100
B
Oak
71/100
C
Price transparency
State access
Molecule range
Onboarding speed
Support responsiveness
Licensing & trust
The spec sheet
| Field | Eden | Oak |
|---|---|---|
| Semaglutide | $239/mo | $250/mo (one flat rate at every dose), read on its order form the afternoon of 15 August; it showed $200/mo that morning |
| Tirzepatide | $349/mo | $300/mo (one flat rate at every dose), read on its order form the afternoon of 15 August; it showed $250/mo that morning |
| Coverage | All 50 states | All 50 states |
| Brand-name | Compounded only | Compounded only |
| Oral option | Injectable only | Injectable only |
| Best for | People who weight clinical transparency and oversight over finding the cheapest rate. | People who want nationwide package-based care and are willing to complete a long intake before learning what they will actually pay. |
| Desk Score | 85/100B | 71/100C |
The verdict
Desk pick — EdenEden takes this head-to-head with the higher Desk Score, 85/100 (B) against 71/100 (C) for Oak. Oak still holds its ground where its strengths line up with yours.
Choose Eden if…
People who weight clinical transparency and oversight over finding the cheapest rate.
$239/mo sema · $349/mo tirz · All 50 states
FDAWarning letter issued to Eden Health International Inc. dba Eden in June 2026. See the FDA warning-letter database.
Choose Oak if…
People who want nationwide package-based care and are willing to complete a long intake before learning what they will actually pay.
$250/mo (one flat rate at every dose), read on its order form the afternoon of 15 August; it showed $200/mo that morning sema · $300/mo (one flat rate at every dose), read on its order form the afternoon of 15 August; it showed $250/mo that morning tirz · All 50 states
Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we file on a provider reads the same either way. Read full breakdowns: Eden · Oak.
Also here
CoreAge Rx tops every dispatch at 94/100
Whichever of these two you lean toward, the Desk's #1-rated provider outscores them both. The Desk's top dispatch: flat all-in pricing, both molecules, all 50 states — no teaser-rate traps.
More head-to-heads
- Eden vs CoreAge Rx
- Oak vs Vaylen
- Eden vs Strut Health
- Oak vs Ondra Health
- Eden vs Invigor Medical
- Oak vs Vytora Health
Or see the full comparison hub and the complete ranking.
Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.